CFTR and cystic fibrosis: Ivacaftor has been prescribed as standard care in the UK to people with CF aged 6 years and over with a G551D mutation since 2013, with access later expanded to individuals with eight other gating mutations, aged six months and older, and with an Arg117His-CFTR mutation.